During 2024 BTCF executed a $45,000 Simple Agreement for Future Equity SAFE with Organamet Bio a research entity conducting studies related to congenital heart disease. The investment is intended as a program-related investment PRI to advance BTCFs charitable purpose of supporting research into novel treatments for HLHS. The amount is reported as an asset in Part II Line 24 and not as a grant expense in Part I. No returns have been realized to date. The program-related investment is made in accordance with 26 CFR Section 53.4944-3. The Board of Directors has formally ratified and approved the investment as a PRI. The primary purpose of this investment is to advance the Foundations charitable mission of supporting congenital heart disease research. Any potential return on investment is incidental to this charitable purpose.